Carney Skyla T, Lloyd Michael L, MacKinnon Shanta E, Newton Doshandra C, Jones Jenelle D, Howlett Allyn C, Norford Derek C
Neuroscience of Drug Abuse Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.
J Neuroimmune Pharmacol. 2009 Sep;4(3):338-49. doi: 10.1007/s11481-009-9153-7. Epub 2009 Apr 14.
In our previous studies, CB(1) cannabinoid receptor agonists stimulated production of cyclic GMP and translocation of nitric oxide (NO)-sensitive guanylyl cyclase in neuronal cells (Jones et al., Neuropharmacology 54:23-30, 2008). The purpose of these studies was to elucidate the signal transduction of cannabinoid-mediated neuronal nitric oxide synthase (nNOS) activation in neuronal cells. Cannabinoid agonists CP55940 (2-[(1S,2R,5S)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol), WIN55212-2 (R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate), and the metabolically stable analog of anandamide, (R)-(+)-methanandamide stimulated NO production in N18TG2 cells over a 20-min period. Rimonabant (N-(piperidin-lyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-H-pyrazole-3-carboxamide), a CB(1) receptor antagonist, partially or completely curtailed cannabinoid-mediated NO production. Inhibition of NOS activity (N ( G )-nitro-L: -arginine) or signaling via Gi/o protein (pertussis toxin) significantly limited NO production by cannabinoid agonists. Ca(2+) mobilization was not detected in N18TG2 cells after cannabinoid treatment using Fluo-4 AM fluorescence. Cannabinoid-mediated NO production was attributed to nNOS activation since endothelial NOS and inducible NOS protein and mRNA were not detected in N18TG2 cells. Bands of 160 and 155 kDa were detected on Western blot analysis of cytosolic and membrane fractions of N18TG2 cells, using a nNOS antibody. Chronic treatment of N18TG2 cells with cannabinoid agonists downregulated nNOS protein and mRNA as detected using Western blot analysis and real-time polymerase chain reaction, respectively. Cannabinoid agonists stimulated NO production via signaling through CB(1) receptors, leading to activation of Gi/o protein and enhanced nNOS activity. The findings of these studies provide information related to cannabinoid-mediated NO signal transduction in neuronal cells, which has important implications in the ongoing elucidation of the endocannabinoid system in the nervous system.
在我们之前的研究中,CB(1) 大麻素受体激动剂可刺激神经元细胞中环鸟苷酸(cGMP)的产生以及一氧化氮(NO)敏感型鸟苷酸环化酶的转位(Jones等人,《神经药理学》54:23 - 30,2008年)。这些研究的目的是阐明大麻素介导的神经元型一氧化氮合酶(nNOS)在神经元细胞中激活的信号转导机制。大麻素激动剂CP55940(2 - [(1S,2R,5S)-5 - 羟基 - 2 - (3 - 羟丙基)环己基] - 5 - (2 - 甲基辛 - 2 - 基)苯酚)、WIN55212 - 2(R(+)-[2,3 - 二氢 - 5 - 甲基 - 3 - [(吗啉基)甲基]吡咯并[1,2,3 - de] - 1,4 - 苯并恶嗪基] - (1 - 萘基)甲酮甲磺酸盐)以及花生四烯乙醇胺的代谢稳定类似物(R)-(+)-甲磺基花生四烯乙醇胺在20分钟内刺激N18TG2细胞产生NO。CB(1) 受体拮抗剂利莫那班(N - (哌啶 - 1 - 基)-5 - (4 - 氯苯基)-1 - (2,4 - 二氯苯基)-4 - 甲基 - H - 吡唑 - 3 - 甲酰胺)部分或完全抑制大麻素介导的NO产生。抑制一氧化氮合酶活性(N(G)-硝基 - L - 精氨酸)或通过Gi/o蛋白进行信号传导(百日咳毒素)可显著限制大麻素激动剂诱导的NO产生。使用Fluo - 4 AM荧光法检测发现,大麻素处理后N18TG2细胞中未检测到钙离子动员。大麻素介导的NO产生归因于nNOS的激活,因为在N18TG2细胞中未检测到内皮型一氧化氮合酶和诱导型一氧化氮合酶的蛋白及mRNA。使用nNOS抗体对N18TG2细胞的胞质和膜组分进行蛋白质印迹分析时,检测到了160 kDa和155 kDa的条带。分别使用蛋白质印迹分析和实时聚合酶链反应检测发现,用大麻素激动剂长期处理N18TG2细胞会使nNOS蛋白和mRNA下调。大麻素激动剂通过CB(1) 受体进行信号传导刺激NO产生,导致Gi/o蛋白激活并增强nNOS活性。这些研究结果提供了与大麻素介导的神经元细胞中NO信号转导相关的信息,这对于当前阐明神经系统中的内源性大麻素系统具有重要意义。